Tarsus awards options and RSUs to officer

Tarsus Pharmaceuticals, Inc. reported that officer Jeffrey S. Farrow received equity awards consisting of a stock option for 30,724 shares and 19,306 restricted stock units, both granted at an exercise price of $0.0000 per share.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. reported that officer Jeffrey S. Farrow received equity awards consisting of a stock option for 30,724 shares and 19,306 restricted stock units, both granted at an exercise price of $0.0000 per share.

According to the grant terms, 25% of the option vests on March 5, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. The 19,306 RSUs vest in four equal annual installments on March 15 of each of 2027, 2028, 2029, and 2030, also subject to ongoing service.

Insider Trade Summary

Grant/Award: 50,030 shares

Grant/Award 2 txns

Insider Farrow Jeffrey S

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,724	$0.00	$0.00
Grant/Award	Restricted Stock Units	19,306	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,724 contracts (Direct); Restricted Stock Units — 19,306 contracts (Direct)

Footnotes (3)

1. F1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. F3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Tarsus Pharmaceuticals (TARS) report in this Form 4?

Tarsus Pharmaceuticals reported that officer Jeffrey S. Farrow received a stock option for 30,724 shares and 19,306 restricted stock units. Both awards were granted at an exercise price of zero dollars per share and are subject to multi-year vesting schedules tied to continued service.

How many stock options were granted to the Tarsus (TARS) officer and how do they vest?

The officer was granted a stock option covering 30,724 shares of common stock. Twenty-five percent of these option shares vest on March 5, 2027, and the remaining shares vest in equal monthly installments over three years, contingent on continuous service with the company.

What are the terms of the restricted stock units granted by Tarsus (TARS)?

The officer received 19,306 restricted stock units, each representing a contingent right to one Tarsus common share. These RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, provided the officer maintains continuous service during the vesting period.

Does the Tarsus (TARS) Form 4 indicate any insider share sales?

The Form 4 shows only acquisition-type transactions for the officer, specifically a stock option grant and an RSU grant. There are no reported sales or disposals of Tarsus common stock in this filing, and all reported transactions are classified as awards or other acquisitions.

Who is the reporting person in the Tarsus Pharmaceuticals (TARS) Form 4 filing?

The reporting person is Jeffrey S. Farrow, identified as an officer of Tarsus Pharmaceuticals with the title provided in the remarks section. The filing shows he directly holds the granted stock options and restricted stock units, subject to the stated vesting schedules and continued service conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrow Jeffrey S

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$74.9	03/05/2026		A		30,724		(1)	03/04/2036	Common Stock	30,724	$0	30,724	D
Restricted Stock Units	(2)	03/05/2026		A		19,306		(3)	(3)	Common Stock	19,306	$0	19,306	D

Explanation of Responses:

1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Remarks:

Chief Financial Officer and Chief Strategy Officer

	/s/ Jeffrey Farrow	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.